Of the 16 converted IPD individuals, eight had plasma NfL and tau levels measured by simplex Simoa platforms and published previously.44 In addition to the IPD-AR cohort, plasma (n = 3; individuals = 2) and CSF (n = 5; individuals = 4) samples from asymptomatic h-GH iCJD-AR individuals were also tested against symptomatic IPD, CJD (sCJD, iCJD and vCJD), and healthy control cohorts, with baseline demographics summarized in Table 1. The gene discussed is MAPT; the disease is Creutzfeldt Jacob disease.